IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that in parallel with the growing adoption of ProSense®, the number of independent, non-sponsored studies of its cryoablation system has significantly increased. In addition to the 12 studies already published in peer reviewed journals and presented in scienti
Von Hippel-Lindau Disease (VHL) or Von Hippel-Lindau Syndrome is a rare genetic disorder caused by a mutation in the VHL gene. It is characterized by the development of benign tumors and cysts in multiple organs.